0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-2 R alpha

IL-2 R alpha

Brief Information

Name:Interleukin-2 receptor alpha chain
Target Synonym:TAC antigen,p55,IL2-RA,Interleukin-2 receptor subunit alpha,IL-2-RA,IL-2R subunit alpha,IL2RA,Interleukin 2 Receptor Subunit Alpha,Interleukin 2 Receptor, Alpha,IL-2 Receptor Subunit Alpha,CD25 Antigen,IDDM10,IMD41,TCGFR,CD25,IL2R,Insulin-Dependent Diabet
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

ILA-H82E6-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human IL-2 R alpha, His,Avitag (Cat. No. ILA-H82E6) inhibits the IL-2-dependent proliferation of Mo7e cells. The EC50 for this effect is 0.57-0.81 µg/mL (Routinely tested).

ILA-H52H9-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) inhibits the IL-2 dependent proliferation of Mo7e cells. The EC50 for this effect is 0.35-0.77 µg/mL (Routinely tested).

ILA-H52H9-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IL-2 R alpha, His Tag (Cat. No. ILA-H52H9) captured on CM5 chip via anti-His antibody, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 29.9 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

ILA-H82E6-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Biotinylated Human IL-2 R alpha, His,Avitag (Cat. No. ILA-H82E6) on SA Biosensor, can bind Human IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 70.2 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

IL2RA,CD25,p55,IL2-RA,IL-2-RA

Background

Interleukin-2 receptor subunit alpha (IL2RA) is also known as IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD antigen CD25, is a type I transmembrane glycoprotein. IL2RA is expressed on activated T cells and regulatory T cells, and is capable of binding IL2 with low affinity by itself. However, a ligand-induced high affinity heterotrimeric receptor complex is produced when IL2RA is associated non-covelently with the IL2 receptor beta and gamma chain, and subsequently initiates the intacellular signal pathways such as MAPK or JAK/STAT. On dendritic cells (DC), CD25 has been previously regarded as an activation marker, while both murine and human DC can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.

Clinical and Translational Updates

Related Molecule

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details
Basiliximab CHT-25; chRFT5; CHI-621; SDZ-CHI-621 Approved Novartis Pharma Ag 舒莱, Simulect Japan Rejection of organ transplantation Novartis Pharma Ag 1998-05-12 Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis Details
Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) Approved Liaoning Satellite Biological Products Research Institute (Limited) Mainland China Neoplasms Liaoning Satellite Biological Products Research Institute (Limited) 2002-02-04 Neoplasms Details
Daclizumab R-35; BIIB-019; RO-247375 Approved Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd Zinbryta, Zenapax United States Multiple Sclerosis Biogen Inc 1997-12-10 Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative Details
Denileukin diftitox E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 Approved Eisai Co Ltd Ontak, Onzar United States Lymphoma, T-Cell, Cutaneous Eisai Inc 1999-02-05 Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma Details
Daclizumab biosimilar (Shanghai CP Guojian) Approved Shanghai Cp Guojian Pharmaceutical Co Ltd 健尼哌 Mainland China Rejection of renal transplantation null 2011-01-12 Rejection of renal transplantation Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details
Inolimomab B-B10; BT-563; MAb-BT-563 Phase 3 Clinical Eusa Pharma, Jazz Pharmaceuticals Graft vs Host Disease Details
Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 HuMikβ1-1 Phase 1 Clinical F. Hoffmann-La Roche Ltd, National Institutes Of Health Leukemia, Lymphoid Details
Basiliximab biobetter (Mabtech/Sorrento) STI-003 Phase 3 Clinical Taizhou Maibo Taike Biotechnology Co Ltd Autoimmune Diseases Details
ANV-419 Phase 2 Clinical Anaveon AG Solid tumours Details
Camidanlumab tesirine ADCT-301 Phase 2 Clinical Genmab, Adc Therapeutics Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details

This web search service is supported by Google Inc.

totop